tbuckley/cabot-search huggingface dataset:
P1-181: Clinical significance of the AKT pathway in small cell lung cancer and other neuroendocrine tumors
Authors: Akihiko Yoshizawa, Junya Fukuoka, Konstantin Shilo, Teri J. Franks, Stephen M. Hewitt, Jin Jen, William D. Travis, Carlos Cordon-Cardo
Journal: Journal of Thoracic Oncology (2007)
Dyspnoea in an older woman
Authors: Joseph Dalby Sinnott, David C Howlett
Journal: BMJ (2016)

An 80 year old woman presented to the emergency department with increasing shortness of breath on exertion and “noisy breathing.” She was easily able to complete full sentences, but on examination there was a faint biphasic stridor. The patient stated that she had been breathing like this for months but that it was slowly worsening. She had no polyphonic expiratory wheeze and on …
Christopher Paton Hindley
Authors: Peter Hindley
Journal: BMJ (2016)

Christopher Paton Hindley (“Chris”) joined the NHS at its inception and was a lifelong advocate. He obtained an open scholarship to study classics at Trinity College, Cambridge, but switched to medicine, studying at Cambridge and University College Hospital in London. After house jobs at UCH, Chris joined the Wigg-Horder Practice in Kentish Town, London. He left to set …
O088 : High-throughput sequencing of the human hepatic progenitor cell niche reveals different signalling pathways depending on the underlying chronic liver disease
Authors: O. Govaere, J. Wouters, W. van Delm, R. van Eijsden, A. Ceulemans, W. van Steenbergen, D. Monbaliu, F. Nevens, T. Roskams
Journal: Journal of Hepatology (2015)
P0593 : Predictive model of HBsAg negativization in inactive HBsAg chronic carriers, mainly caucasian
Authors: M.L. González-Diéguez, C.A. Navascués, G. Albines, Mercedes Rodríguez, V. Cadahía, M. Varela, R. Pérez, Manuel Rodríguez
Journal: Journal of Hepatology (2015)
Multivariable Time-Dependent Analysis Of The Impact Of 5 Azacitidine In Patients With Lower-Risk Myelodysplastic Syndrome and Unfavorable Specific Lower-Risk Score
Authors: Jose F Falantes, Regina García Delgado, Cristina Calderón, David Valcarcel, Julia Montoro, Dunia De Miguel, Francisco J Márquez-Malaver, Alicia Bailen, Joan Bargay, Teresa Bernal, Jose R Gonzalez-Porras, Mar Tormo, Fernando Ramos, Rafael Andreu, Blanca Xicoy, Benet Nomdedeu, Salut Brunet, Joaquin Sanchez, Antonio Fernández Jurado, Santiago Bonanad, Ildefonso Espigado, Jose Antonio Pérez-Simón, Guillermo Sanz
Journal: Blood (2013)
Expression Pattern and Prognostic Impact of Vascular Endothelial Growth Factors VEGF and VEGF-C and Their Receptors Flt-1, KDR and Flt-4 in Peripheral T-Cell Lymphomas.
Authors: Judit M. Jørgensen, Flemming B. Sørensen, Knud Bendix, Johan L. Nielsen, Anette D. Funder, Tapio Tainola, Marika Karkkainen, Annette B. Sørensen, Finn S. Pedersen, Astrid V. Kühle, Francesco d’Amore
Journal: Blood (2007)
Fitness consequences of polymorphic inversions in the zebra finch genome
Authors: Ulrich Knief, Georg Hemmrich-Stanisak, Michael Wittig, Andre Franke, Simon C. Griffith, Bart Kempenaers, Wolfgang Forstmeier
Journal: Genome biology (2016)

Inversion polymorphisms constitute an evolutionary puzzle: they should increase embryo mortality in heterokaryotypic individuals but still they are widespread in some taxa. Some insect species have evolved mechanisms to reduce the cost of embryo mortality but humans have not. In birds, a detailed analysis is missing although intraspecific inversion polymorphisms are regarded as common. In Australian zebra finches (Taeniopygia guttata), two polymorphic inversions are known cytogenetically and we set out to detect these two and potentially additional inversions using genomic tools and study their effects on embryo mortality and other fitness-related and morphological traits. Using whole-genome SNP data, we screened 948 wild zebra finches for polymorphic inversions and describe four large (12–63 Mb) intraspecific inversion polymorphisms with allele frequencies close to 50 %. Using additional data from 5229 birds and 9764 eggs from wild and three captive zebra finch populations, we show that only the largest inversions increase embryo mortality in heterokaryotypic males, with surprisingly small effect sizes. We test for a heterozygote advantage on other fitness components but find no evidence for heterosis for any of the inversions. Yet, we find strong additive effects on several morphological traits. The mechanism that has carried the derived inversion haplotypes to such high allele frequencies remains elusive. It appears that selection has effectively minimized the costs associated with inversions in zebra finches. The highly skewed distribution of recombination events towards the chromosome ends in zebra finches and other estrildid species may function to minimize crossovers in the inverted regions.
Etude de l'introduction d'une vaccination généralisée de la grippe chez les personnes âgées aux Pays-Bas
Authors: G. A. van Essen
Journal: Eurosurveillance (1998)

Depuis de nombreuses annees aux Pays-Bas, la vaccination de la grippe est geree par les medecins generalistes aupres desquels chaque personne est enregistree. Sur dix cabinets medicaux, neuf utilisent un des six systemes d'information de medecine generale agrees (GPIS : general practice information systems). L'utilisation croissante de dossiers medicaux informatises dans des pays comme les Pays-Bas et le Royaume Uni peut etre consideree comme un des progres majeurs des dernieres annees en ce qui concerne la prevention en population generale. La liste des patients et l'automatisation rendent possible une prevention systematique en medecine generale.
XRCC5 Plays an Important Role in Homologous Recombination, Genome Stability and Survival of Myeloma Cells
Authors: Edward Laane, Purushothama Nanjappa, Subodh Kumar, Florence Magrangeas, Stephane Minvielle, Hele Everaus, Kenneth C Anderson, Herve Avet-Loiseau, Masood A Shammas, Nikhil C. Munshi
Journal: Blood (2015)
Real-world utilization of targeted therapy in cancer treatment.
Authors: J. Subramanian, A. Vlahiotis, S. Frazee, K. Snider, S. Devarakonda, R. Govindan
Journal: Journal of Clinical Oncology (2011)

e16618 Background: Targeted drugs are highly effective in patients with a well specified molecular target, such as imatinib for patients with chronic myelogenous leukemia. However, results from prospective studies have shown only modest improvement in outcomes for unselected patients with cancer receiving targeted drugs. Very little data exist regarding the true impact of targeted therapy in routine clinical practice. Methods: Based on the published data, intolerable side effects are infrequent with targeted drugs and discontinuation is primarily due to progressive disease. Identifying the proportion of patients who are “minimum-users” defined as those who failed to refill their prescription more than once, (prescription claim ≤ 60 days) would be one way of assessing treatment efficacy in routine practice. We studied claims from 2007 to 2009 for imatinib (I), lapatinib (L), erlotinib (E), sorafenib (S), sunitinib (Su) and everolimus (Ev) in Express Scripts pharmacy claims database. Patient’s age, gender, duration of prescription was identified. The database does not include information on diagnosis or outcomes. Results: Prescription claims for 14,300 patients were identified (Table). The proportion of patients who did not refill their prescription after 60 days was; I (9.9%), L (20.9%), E (31%), S (38.3%), Su (43.9%) and Ev (56.2%). The proportion of prescription claims that were ≤ 60 days was significantly different between drugs prescribed to biomarker selected patients (I+L) versus drugs prescribed to unselected patients (E+S+Su+Ev); 12.3% vs. 34.4%, p<0.0001. The cost of drug for claims ≤ 60 days was; I $2,695,945, L $1,534,059; E $12,878,656; S $4,937,772, Su $9,280,050 and Ev $218,916. Conclusions: Targeted therapy for cancer in unselected patients leads to very high rates of early discontinuation. I L E S Su Ev Total p N (%) 3,945(27.6) 1,160(8.1) 6,140(42.9) 1,544(10.8) 1,479(10.3) 32(0.2) 14,300 Median age (range) 58(18-96) 56(26-91) 65(19-97) 62(19-93) 62(19-92) 61(38-87) 62(18-97) <.0001 Men N (%) 2,118(53.7) 25(2.2) 2,920(47.6) 1,138(73.7) 1,007(68.1) 25(78.1) 7,233(50.6) > 60 day supply N (%) 3,554(90.1) 917(79.1) 4,236(69.0) 952(61.7) 829(56.1) 14(43.8) 10,502(73.4) <.0001 60 day cost (median) $6,895 $6,313 $6,764 $10,183 $14,277 $12,162 $6,930 <.0001
Allogeneic Hematopoietic Cell Transplantation for Adult Patients with ALL: Current Results and Prognostic Factors. an Analysis from Acute Leukemia Working Party of the EBMT
Authors: Sebastian Giebel, Myriam Labopin, Liisa Volin, Gerard Socie, Ibrahim Yakoub-Agha, Mauricette Michallet, Jakob R Passweg, Noel-Jean Milpied, Patrice Chevallier, Anne Huynh, Tony Marchand, Jean-Henri Bourhis, Nathalie Fegueux, Johan Maertens, Xavier Poiré, Sridhar Chaganti, Alessandro Rambaldi, Mohamad Mohty, Arnon Nagler
Journal: Blood (2015)
TCT-637 Transcatheter Aortic Valve Implantation in Patients with Small Aortic Annuli Using the Edwards SAPIEN XT 20mm Balloon-Expanding Heart Valve: Early Clinical Results from A Multi-Center Registry
Authors: Rishi Puri, Hardy Baumbach, Harindra C. Wijeysundera, Asim Cheema, Ralf Mueller, Simon Redwood, Jonathan Byrne, Helene Eltchaninoff, Kaj-Erik Klaaborg, Marc Pelletier, Christophe Dubois, Marc Ruel, Marko P. Virtanen, Verena Veulemans, Jan-Malte Sinning, Alfredo Giuseppe Cerillo, Francesco Meucci, Caterina Gandolfo, Pieter R. Stella, Roberto Blanco, Matthias Gotberg, Douglas F. Muir, Jean-Paul Herzog, Martin Thoenes, Philippe Pibarot, Emilie Pelletier Beaumont, Josep Rodes-Cabau
Journal: Journal of the American College of Cardiology (2015)
Comprehensive population-wide detection of Lynch syndrome in Iceland.
Authors: Sigurdis Haraldsdottir, Thorunn Rafnar, Wendy L Frankel, Sylvia Einarsdottir, Asgeir Sigurdsson, Heather Hampel, Petur Snaebjornsson, Gisli Masson, Daniel Weng, Birte Kehr, Ahmet Yilmaz, Stefan Haraldsson, Patrick Sulem, Tanios S. Bekaii-Saab, Megan P. Hitchins, Colin C. Pritchard, Albert De La Chapelle, Jon G. Jonasson, Richard M. Goldberg, Kari Stefansson
Journal: Journal of Clinical Oncology (2016)

1542 Background: Lynch syndrome (LS) is caused by germline mutations in mismatch repair (MMR) genes (MLH1, MSH2, MSH6, PMS2) or EPCAM, and is associated withincreased cancer risk. The incidence of LS in Iceland is unknown. We investigated the incidence of LS and etiology of MMR deficiency (dMMR) by screening all Icelandic individuals diagnosed with colorectal cancer (CRC) over a decade for dMMR and correlated the results with complete information on LS gene variation and cancer incidence. Methods: Immunohistochemistry (IHC) for MLH1, MSH2, MSH6, and PMS2 was performed on all CRC cases diagnosed from 2000-2009 in Iceland. Cases with MLH1/PMS2 deficient tumors underwent MLH1 hypermethylation (MLH1-hm) testing. Information on MMR gene variation in the Icelandic population was extracted from a genetic database. Germline genotyping was done on peripheral blood mononuclear cells obtained from all patients with dMMR tumors and 78.2% of patients with MMR proficient tumors. All unexplained dMMR cases underwent whole-genome sequencing and tumor ColoSeq to identify somatic MMR mutations. Results: Of 1182 patients (97.8%) with tumor available for MMR IHC, 132 (11.2%) had dMMR. Ninety (7.6%) dMMR cases were MLH1-hm, 21 (1.8%) had LS and 16 (1.4%) double somatic MMR mutations. Overall, LS accounted for 2.3% of all CRCs. Two mutations, MSH6 p.Leu585Pro and PMS2 p.Pro246Cysfs*3, caused 77.8% of LS in CRC patients. Three CRC patients had private mutations in MSH6 and one patient had an interchromosomal translocation in MLH1. Three founder mutations, MSH6 p.Leu585Pro, PMS2 p.Pro246Cysfs*3, and PMS2 p.Met1?had a combined population frequency of 0.442%, affecting 1 in 226 individuals and displayed odds ratios of 10.1, 3.6 and 2.2 for CRC, respectively. Fourteen MMR variants of unknown significance (VUS) in the population were not associated with increased cancer risk. Conclusions: Founder mutations in MSH6 and PMS2 prevail in Iceland. Only one case each of MLH1 and MSH2 mutations occurred. The LS population incidence of 0.442% is the highest ever reported but given the lower cancer penetrance linked to MSH6 and PMS2, only 2.3% of CRC are caused by LS. The MSH6 p.Leu585Pro mutation can be reclassified as a pathogenic mutation and 14 MMR VUS can be reclassified as benign.
Impact of spontaneous reperfusion in diabetics with acute myocardial infarction
Authors: Kevin R Baine, Yuling Fu, Christopher B Granger, Chrislian W Hamm, David R Holmes, William W O'Neill, Ricardo Seabra-Gomes, Matthias E Pfisterer, Frans Van de Werf, Paul W Armstrong
Journal: Journal of the American College of Cardiology (2008)
Population admixture analysis of Hispanic women at risk for <i>BRCA1</i> or <i>BRCA2</i> mutations in high-risk clinic populations.
Authors: G. P. Larson
Journal: Journal of Clinical Oncology (2010)

e12045 Background: We have sought to characterize the ancestral origins of a variety of BRCA1 and BRCA2 mutations from high-risk Hispanic women. Our prior work (Weitzel, et al CEBP 14:1666, 2005) has demonstrated conserved haplotypes through the BRCA1 interval for several recurrent mutations from high-risk Hispanic patients, some exclusive to families with Mexican American or Spanish ancestry. Methods: To better define the global ancestral origins of our Latinas (Caribbean/African vs AmerIndian) we have employed Ancestry Informative Markers (AIMs) (n∼100) to characterize the intercontinental admixture of two cohorts of high-risk patients recruited through both U.S. (City of Hope and Columbia University) and Colombian ( University of Toronto) registries. Results: Using a Bayesian population clustering algorithm in combination with reference individuals from the HapMap Project and HGDP we are able to determine the proportions of AmerIndian, West African, Caucasian, and East Asian genetic ancestry in these patients. These genetic data can be cross-validated with self-reported ancestry (country of birth, and city-when available). Conclusions: For individuals with significant AmerInd ancestry we are supplementing this set with additional Mestizo-specific AIMs from distinct geographic regions within Mexico to develop additional fine structure. This information will be used to identify germline BRCA mutations common to specific ancestral backgrounds, and to distinguish distinct subset populations that are included in the Hispanic category. No significant financial relationships to disclose.
Venoarterial extracorporeal membrane oxygenation for refractory cardiogenic shock post-cardiac arrest
Authors: Marc Pineton de Chambrun, Nicolas Bréchot, Guillaume Lebreton, Matthieu Schmidt, Guillaume Hekimian, Pierre Demondion, Jean-Louis Trouillet, Pascal Leprince, Jean Chastre, Alain Combes, Charles-Edouard Luyt
Journal: Intensive Care Medicine (2016)
P1-188: Early lung cancer detection by sputum examination and autofluorescence bronchoscopy (AF) in smokers with silicosis
Authors: Bing Lam, Moira M. Chan-Yeung, Chi-Chiu Leung, Sy Lam, Amy H. Cheung, Maria Wong, Cheuk-Ming Tam, Wah-Kit Lam
Journal: Journal of Thoracic Oncology (2007)
Implementation of distress screening for breast cancer patients.
Authors: Jill Bryant, Helen Colleen Silva, Greg Mapp, Daphne Terrell
Journal: Journal of Clinical Oncology (2016)

196 Background: Cancer is a complex disease process. Patients experience psychological, social, financial, and behavioral issues that can interfere with their treatment plan and adversely affect their outcomes. Distress should be measured as the 6th Vital Sign. Consequences of distress can cause deterioration of Quality of Life; produce higher levels of pain; longer rehabilitation; reduced adherence to treatment with less efficacy; and shorter survival expectancy. Methods: Problem exists with a lack of screening patients’ level of distress during breast cancer experience within their cancer care continuum. Goal was to improve the prevalence of distress screening of breast cancer patients from 0% to 50% within 3 months. Cause and effect analysis showed evidence of areas for improvement. Improvements and interventions included: education on stress and psychosocial assessment; developing a distress screening tool; and developing inclusion criteria for patient screening. Screenings were completed on first follow-up visit after diagnosis with continuation of assessment every three months for the first year. A distress screening tool with a thermometer illustration was provided to the patients for them to rate amount of distress experienced in the past week. Scoring was “0 = no distress to 10 = extreme stress.” The tool also included Yes/No questions. A value of 4 or greater on the thermometer or any question marked “Yes” on the questionnaire was considered a positive screen. Results: In addition to developing a tool, a template was implemented in the electronic medical record. Opportunities for assistance with distress were discovered based on patients’ responses where interventions and follow-ups with the patient were provided. Conclusions: A process was developed and implemented to integrate and monitor on-site psychosocial distress screening and referral for provision of psychosocial care. A small number of patients analyzed met criteria during a short period of time. The percentage of distress screenings completed improved from 0% to 92%. [Table: see text]
Concomitant gemcitabine, cisplatin, anastrazole, and zoledronic acid in HER2-negative metastatic breast cancer in postmenopausal women.
Authors: S. Ahmed, A. W. Goraya, M. Hafeez, H. Khan
Journal: Journal of Clinical Oncology (2010)

1129 Background: There is no preclinical or clinical evidence against the concomitant use of aromatase inhibitors with systemic chemotherapy in breast cancer. Despite this fact it is rarely used in clinical practice today. Aromatase inhibitors have the significant therapeutic contribution in the management of hormone responsive disease in postmenopausal women and ideally their use shall not be delayed till the completion of chemotherapy. Therefore, we have designed this study to evaluate the efficacy and toxicity of concomitant gemcitabine, cisplatin, anastrazole, and zoledronic acid. Methods: Patients with visceral or visceral and bone metastases were included. Postmenopausal, ER-/PR-positive and HER2neu-negative patients with a KPS of > 70, adequate marrow, hepatic, and renal function were enrolled. Metastatic brain disease and bone as the only site of disease was excluded. Gemcitabine 1,250 mg/m2 was given on day 1 and 8, with cisplatin 70 mg/m2 on day one of three weekly cycles. Anastrazole 1 mg was given daily from the day one and zoledronic acid 4 mg every 4 weeks from day 2. CTCAE version 3 and RECIST were used. Results: From April 2006 to November 2009, 58 patients were enrolled. Median age was 57 years (range 45–70). No grade 3/4 toxicity was seen. Grade 2 fatigue and arthralgia was seen in 10 (17.2%) and 4 (6.9%) patients, respectively. Hot flashes were seen in 5 (8.6%), rash in 7 (12.1%), N/V in 15 (25.9%) and constipation in 7 (12.1%) patients. Anemia was seen in 16 (27.6%), neutropenia in 14 (24.1%) and thrombocytopenia in 9 (15.5%) patients. None had skeletal-related events. Eleven patients (18.9%) had a CR, 34 patients (58.6%) had PR, 1 patient had PD and remaining had SD. At a median follow up of 24 months (range 8-40) 12 patients have died. Median time to progression is 14 months. Conclusions: This therapy yields a high response rate with durable responses and has a manageable toxicity profile. No significant financial relationships to disclose.
Triple-negative breast cancers: Biomarkers and outcomes.
Authors: L. Malorni, P. B. Shetty, S. G. Hilsenbeck, M. F. Rimawi, R. M. Elledge, C. De Angelis, C. K. Osborne, S. De Placido, G. Arpino
Journal: Journal of Clinical Oncology (2010)

10621 Background: ER/PR/HER2-negative [triple negative (TN)] breast cancer is associated with poor outcome, as is EGFR expression. However, studies on well characterized, large populations of TN patients with long term follow up are lacking. In this study we analyze clinical outcomes of TN breast cancer and the implications of EGFR expression. Methods: Clinical and biologic features, time to recurrence (TTR), and overall survival (OS) were compared in TN vs ER positive, PR positive, HER2-negative [estrogen driven (ED)] tumors. Of 2,567 patients with complete ER, PR, and HER2 data in our database, 253 were TN and 1036 were ED. Results: Compared to ED, TN tumors were larger (>2 cm in 55% vs. 47%, p=.02), more proliferative (high S-phase 54% vs. 17%, p<.0001), and more aneuploid (64% vs. 43%, p<.0001), but did not significantly differ in nodal status. TN tumors were 7 times more likely than ED to be EGFR positive (≥10 fmol/mg by radioligand binding assay, 49% vs. 7%, p<.0001). In the TN cohort, EGFR positive (n=124) were larger (>2 cm in 65% vs. 45%, p=.0018), more proliferative (high S-phase 69% vs. 41%, p<.0001), and more aneuploid, (80% vs. 50%, p<.0001) than EGFR negative tumors (n=129). Adjuvant treated TN patients had shorter TTR, p<.0001, and OS, p<.0001, than ED patients. However, in untreated patients (n=539), 8-year survival did not show significant differences in either TTR or OS. Surprisingly, among TN patients, EGFR expression was not associated with worse outcome. Conclusions: TN tumors are larger and have higher proliferation, more genomic instability, and higher EGFR than ED tumors, and have a worse outcome in systemically treated patients. EGFR expression in TN tumors, although associated with a distinct, more aggressive phenotype does not predict for worse long term survival in our cohort. High genomic instability makes TN tumors attractive targets for agents that interfere with DNA repair. Author Disclosure Employment or Leadership Position Consultant or Advisory Role Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Onyx